Headache and Migraine

In a systematic review, investigators aim to understand the mechanisms for comorbid bipolar disorder and migraine, as well as therapeutic targets.

In addition to reducing the frequency of migraine days, galcanezumab may also potentially decrease disabling non-pain symptoms of migraine on days when migraine is present.

The relatively new biologic therapies for migraine demonstrated low immunogenicity rates and rare adverse events.

Pharmacists are well positioned to support the care of patients with migraines and offer advice on treatments.

Patients reported more frequent and severe migraines, along with overuse of analgesics.

A study observed gaps in migraine knowledge in women’s health care providers. Pharmacists can play a role in provider education on prophylaxis and treatment.

Investigators observed that about half of patients treated with rimegepant showed a 50% or greater reduction in how many moderate-to-severe migraine days they experienced per month.

Pharmacists can provide education on migraine prophylaxis for better outcomes.

Researchers examined the 3 debated strategies for treating medication overuse headache.

A poster presented at the ASHP 2020 Midyear Clinical Meeting and Exhibition indicated opportunities for community pharmacists to improve outcomes for patients with migraines.

The pharmaceutical company has submitted a New Drug Application for dihydroergotamine mesylate for fast and lasting whole migraine relief in adults with and without aura.

Add value by optimizing medications, decreasing pill burden.

Results from a phase 3 study showed that galcanezumab-gnlm (Emgality, Eli Lilly) significantly improved work productivity and health and well-being between migraine attacks.

Migraine is one of the most common neurologic disorders in children and adolescents with a prevalence of 7.7%.

Officials with the FDA have approved celecoxib oral solution 25 mg/mL (Elyxyb, Dr. Reddy’s Laboratories) for the acute treatment of migraine with or without aura in adults.

Rimegepant (Nurtec ODT, Biohaven Pharmaceuticals) reduced monthly migraine days in patients with episode and chronic migraine in a clinical trial.

On December 23, 2019, the FDA approved ubrogepant for the acute treatment of migraine with and without aura in adult patients.

Rimegepant (Nurtec ODT, Biohaven),a fast-acting orally disintegrating tablet, delivers quick and sustained efficacy for patients with migraine.